Keyphrases
Arterial Properties
100%
Papillary Thyroid Carcinoma
96%
Thyroid Cancer
85%
Cardiovascular Risk
83%
Differentiated Thyroid Carcinoma
65%
Isoflavone Derivatives
63%
Neck Dissection
63%
Myocardial Infarction Patients
52%
ST-elevation Myocardial Infarction (STEMI)
52%
Confidence Interval
52%
Arterial Stiffness
51%
Endothelial Function
49%
Cardiovascular Morbidity
48%
Body Composition
47%
Thyroid Cancer Survivors
47%
Pulse Wave Velocity
45%
Acute Kidney Injury
44%
Total Thyroidectomy
44%
Subclinical Hypothyroidism
44%
O-carboxymethyl
44%
Daidzein
44%
Oral Calcium
42%
Long-term Mortality
42%
Calcium Overload
42%
Therapeutic Levels
42%
Thyroid Carcinoma Cells
42%
Recurrence Pattern
42%
Percutaneous Coronary Intervention
42%
Metabolic Syndrome
42%
Thyroid Hormones
35%
Estrogen Receptor
35%
Hormone Levels
32%
Coronary Artery Disease
31%
Vascular Parameters
31%
Diabetes
30%
Older Adults
29%
Cardiovascular Disease
29%
Israeli
28%
Human Thyroid
28%
Flow-mediated Dilation
28%
Cardiovascular Mortality
28%
Augmentation Index
27%
Normal Thyroid
26%
Vitamin D Receptor
26%
Thyroidectomy
26%
Coronary Risk Factors
26%
Diabetic Patients
26%
Primary Hyperparathyroidism (pHPT)
25%
Population-based Cohort Study
25%
Growth Inhibition
25%
Medicine and Dentistry
Differentiated Thyroid Cancer
63%
Neck Dissection
63%
Thyroid Cancer
63%
Recurrent Disease
56%
Thyroidectomy
53%
Cardiovascular System
51%
Cardiovascular Risk
50%
Papillary Thyroid Cancer
49%
Endothelial Function
47%
Myocardial Infarction
46%
Metabolic Syndrome
42%
Subclinical Hypothyroidism
42%
Percutaneous Coronary Intervention
42%
Isotopes of Calcium
42%
Cohort Analysis
42%
Ischemic Heart Disease
37%
Hormone Determination
36%
Acute Kidney Injury
36%
Thyrotropin
35%
Pulse Wave Velocity
33%
Diabetes
32%
Dyslipidemia
31%
Arterial Stiffness
29%
Low Density Lipoprotein Cholesterol
27%
Diabetes Mellitus
27%
Primary Hyperparathyroidism
25%
Diastolic Blood Pressure
25%
Retrospective Cohort Study
24%
Maturity Onset Diabetes of the Young
24%
Primary Percutaneous Coronary Intervention
23%
Meta-Analysis
23%
Evolocumab
21%
Substitution Therapy
21%
Aldosterone Release
21%
Quality Adjusted Life Year
21%
Resistance Training
21%
1 Alkyl 2 Acetylglycerophosphocholine Esterase
21%
Resting Energy Expenditure
21%
Daidzein
21%
Parathyroid Adenoma
21%
Smouldering Myeloma
21%
Hyperglycemia
21%
Hemoglobin A1c
21%
Self-Diagnosis
21%
Estrogen Receptor
21%
Renal Failure
21%
All Cause Mortality
21%
Multiple Myeloma
21%
Clinical Nutrition
21%
Randomized Clinical Trial
21%
Pharmacology, Toxicology and Pharmaceutical Science
Thyroid Cancer
73%
Thyroid Papillary Carcinoma
67%
Isoflavone
63%
Thyroid Carcinoma
54%
Cardiovascular Risk
50%
Primary Hyperparathyroidism
49%
Heart Infarction
48%
Daidzein
44%
Subclinical Hypothyroidism
42%
All Cause Mortality
42%
Ischemic Heart Disease
37%
Acute Kidney Failure
36%
Estrogen Receptor
34%
Thyrotropin
33%
Messenger RNA
32%
Cohort Study
28%
Diseases
27%
Vitamin D Receptor
26%
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
25%
Diabetes Mellitus
24%
Dyslipidemia
23%
Differentiated Thyroid Cancer
22%
Cardiovascular Disease
21%
Statin (Protein)
21%
1 Alkyl 2 Acetylglycerophosphocholine Esterase
21%
Calcitriol
21%
Goiter
21%
Hyperglycemia
21%
Randomized Clinical Trial
21%
Hemoglobin A1c
21%
Sorafenib
21%
Recurrent Disease
21%
Kidney Failure
21%
Parathyroid Adenoma
21%
Ferritin
21%
Coronavirinae
21%
Adverse Outcome
21%
Frailty
21%
Random Effects Model
21%
Nonalcoholic Fatty Liver
21%
Antithyroid Agent
21%
Malignant Neoplasm
16%
Synapsin I
16%
ST Segment Elevation Myocardial Infarction
16%
Low Density Lipoprotein Cholesterol
15%
Hypothyroidism
10%
Hepatitis B Virus
10%
Alcohol Liver Disease
10%
Hepatitis C Virus
10%
Liver Disease
10%